Fig. 6: Combined treatment with a USP7 inhibitor and melatonin induces additive anti-NSCLC activity.
From: PRMT1 promotes Warburg effect by regulating the PKM2/PKM1 ratio in non-small cell lung cancer
A Western blot analysis of Cyclin A in AMI-1 (50 μM) and melatonin (2 mM)-treated H1299 cells. B Proliferation rates of H1299 cells treated with AMI-1 and melatonin evaluated via the CCK-8 assay. C H1299 cells were treated with the indicated amounts of P5091 for 48 h and PRMT1 protein levels determined via immunoblotting. D Western blot analysis of Cyclin A in H1299 cells treated with P5091 (10 μM) and melatonin. E Proliferation rates of P5091- and melatonin-treated H1299 cells evaluated via the CCK-8 assay. F Determination of tumor growth over time in nude mice (5 mice/group) transplanted with A549 cells and treated with melatonin (20 mg/kg). G Determination of tumor growth over time in nude mice (5 mice/group) transplanted with H1299 cells and treated with melatonin (20 mg/kg), P5091 (10 mg/kg), or a combination of the two drugs. Error bars, mean ± SD. ns (non-significant), P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
